MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Начало・Списък с акции・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

75.09 -1.83

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

74.75

Максимум

75.26

Ключови измерители
By Trading Economics
Приходи	-100M -229M
Продажби	46M 203M
Марж на печалбата	-112.808
Служители	1,402
EBITDA	4.7B 4.6B

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+29.68% upside

Дивиденти
By Dow Jones
Следващи печалби	29.04.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1.4B 12B
Предишно отваряне	76.92
Предишно затваряне	75.09

Настроения в новините

By Acuity

50%

156 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

29.78 / 33.645 Подкрепа & съпротива

Ionis Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.04.2026 г., 17:04 ч. UTC

Значими двигатели на пазара

FDA Rejects Replimune's Melanoma Drug for a Second Time

11.04.2026 г., 09:30 ч. UTC

Печалби

After the Great EV Slowdown, High Gas Prices Are Tempting Americans Back -- WSJ

11.04.2026 г., 08:20 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

11.04.2026 г., 08:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

11.04.2026 г., 08:20 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

11.04.2026 г., 00:00 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Big Yachts, Big Bucks -- Barrons.com

10.04.2026 г., 21:55 ч. UTC

Придобивния, сливания и поглъщания

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10.04.2026 г., 21:01 ч. UTC

Печалби

Cango Inc.: Files Annual Report on Form 20-F With SEC

10.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

10.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

10.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

10.04.2026 г., 20:31 ч. UTC

Пазарно говорене

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10.04.2026 г., 20:10 ч. UTC

Придобивния, сливания и поглъщания

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10.04.2026 г., 19:15 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

10.04.2026 г., 19:15 ч. UTC

Пазарно говорене

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10.04.2026 г., 19:08 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

10.04.2026 г., 19:08 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures End Week Lower -- Market Talk

10.04.2026 г., 18:38 ч. UTC

Пазарно говорене

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

10.04.2026 г., 18:25 ч. UTC

Пазарно говорене

Значими събития в новините

Precious Metals Finish With Weekly Gains -- Market Talk

10.04.2026 г., 18:05 ч. UTC

Пазарно говорене

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

10.04.2026 г., 17:31 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

10.04.2026 г., 17:26 ч. UTC

Печалби

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

10.04.2026 г., 17:10 ч. UTC

Пазарно говорене

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

10.04.2026 г., 17:00 ч. UTC

Значими събития в новините

Construction Business Taking a Hit From Iran Conflict -- WSJ

10.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

10.04.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

10.04.2026 г., 16:12 ч. UTC

Печалби

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

10.04.2026 г., 16:11 ч. UTC

Печалби

Partners Group: Traditional Programs Contributed $3.3B

10.04.2026 г., 16:10 ч. UTC

Печалби

Partners Group: $5B of New Commitments Came From Bespoke Solutions

10.04.2026 г., 16:10 ч. UTC

Печалби

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

Сравнение с други в отрасъла

Ценова промяна

Ionis Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

29.68% нагоре

12-месечна прогноза

Среден 97.48 USD 29.68%

Висок 120 USD

Нисък 72 USD

Според 15 анализатори от Wall Street, предложили 12-месечна ценова цел за Ionis Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

15 ratings

Купи

Задържане

Продай

Според 15 анализатори, дали борсови рейтинги на Ionis Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

29.78 / 33.645Подкрепа & съпротива

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Настроение

By Acuity

156 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.